Do platinum salts fit all triple negative breast cancers?. (July 2016)

• Record Type: Journal Article
• Authors: Gerratana, L.; Fanotto, V.; Pelizzari, G.; Agostinetto, E.; Puglisi, F.
• Is Part Of: Cancer treatment reviews. Volume 48(2016)
• Page Start: 34
• Page End: 41
• Publication Date: 2016-07
• Subjects: BRCAness -- Carboplatin -- Cisplatin -- Triple negative breast cancer; Cancer -- Periodicals; Cancer -- Treatment -- Periodicals; Neoplasms -- therapy -- Periodicals; Cancer -- Périodiques; Cancer -- Traitement -- Périodiques; Cancer -- Treatment; Electronic journals; Periodicals; 616.99406
• DOI: 10.1016/j.ctrv.2016.06.004
• Languages: English
• ISSNs: 0305-7372

Abstract

Highlights: The phenotype of BRCA wild-type TNBC often resembles the one of BRCA-related cancer. BRCAness can be caused by epigenetic alterations or a RAD51 complex impairment. Rearrangements analysis by high-throughput technologies predict response to platinum. In neoadjuvant setting adding carboplatin improves pCR rates selectively in TNBC. First-line carboplatin improves response rate only in BRCA1/2-mutated TNBC. Abstract: Triple-negative breast cancer (TNBC) is an aggressive disease with limited treatment options and poor prognosis once metastatic. Pre-clinical and clinical data suggest that TNBC could be more sensitive to platinum-based chemotherapy, especially among BRCA1/2-mutated patients. In recent years, several randomised trials have been conducted to evaluate platinum efficacy in both early-stage and advanced TNBC, with conflicting results especially for long-term outcomes. Experimental studies are now focusing on identifying biomarkers of response to help selecting patients who may benefit most from platinum-based therapies, including BRCA1/2 mutational status and genomic instability signatures (such as HRD-LOH or HRD-LST scores). A standard therapy for TNBC is still missing and platinum-based regimens represent an emerging therapeutic option for selected patients with a defect in the homologous recombination repair system. The identification of these patients through validated biomarker assays will be crucial to optimize the use of currently approved agents in TNBC.